All In Biotech

Drug Trial Radar · NCT07288580

A Clinical Trial of EHT102 Injection in Pediatric Patients With Biallelic hOTOF Mutations

A Phase Ⅰ/Ⅱ, Multicenter, Single-arm, Open-label Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHT102 Injection in Pediatric Patients With Biallelic hOTOF Mutations

Last checked: Nov 19, 2026Latest source record: Apr 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Apr 2, 2026

Primary completion

Jun 30, 2028

Study completion Dec 30, 2033

Sponsor

Sponsor type
Industry
First posted
Dec 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, single-arm, open-label Phase I/II clinical trial, which is designed to evaluate the safety, tolerability and efficacy of EHT102 injection in treating congenital hearing loss secondary to biallelic mutations of OTOF (DFNB9).Up to 30 pediatric participants (A maximum of 15 participants will be enrolled in each of the United States and China) will be enrolled and dosed with EHT102. The dose-escalation phase (Phase I) includes two predefined dose cohorts (3 participants per cohort), with sequential enrollment from low to high dose. During dose escalation, each participant will receive a unilateral EHT102 injection followed by safety observation.

Conditions

  • Treatment of Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)

Interventions

  • EHT102 InjectionDrug

    EHT102 injection is a dual-vector gene therapy product developed for the treatment of OTOF-related hearing loss.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Related Adverse Events as Assessed by CTCAE v5.0Time frame: Up to week 52
  2. Proportion of Participants Achieving a Hearing Sensitivity Threshold of ≤70 dB by behavioral audiometryTime frame: Up to week 26

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Eye & ENT Hospital of Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.